53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp

State Street Corp purchased a new stake in Pharvaris (NASDAQ:PHVS - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 53,980 shares of the company's stock, valued at approximately $1,000,000. State Street Corp owned about 0.17% of Pharvaris as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PHVS. HighVista Strategies LLC grew its holdings in Pharvaris by 35.9% during the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock worth $422,000 after acquiring an additional 6,018 shares during the last quarter. Sofinnova Investments Inc. grew its stake in shares of Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company's stock worth $11,309,000 after purchasing an additional 16,862 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris in the third quarter valued at $906,000. Patient Square Capital LP bought a new position in Pharvaris during the 3rd quarter worth $4,488,000. Finally, Deerfield Management Company L.P. Series C lifted its holdings in Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company's stock worth $26,269,000 after buying an additional 335,687 shares during the period.

Pharvaris Trading Down 0.1 %

PHVS stock traded down $0.01 during midday trading on Friday, hitting $18.53. The stock had a trading volume of 119,281 shares, compared to its average volume of 76,540. The firm has a market cap of $590.00 million, a P/E ratio of -6.62 and a beta of -3.17. The business has a fifty day moving average price of $20.76 and a two-hundred day moving average price of $19.36. Pharvaris has a 1-year low of $15.37 and a 1-year high of $33.00.

Analysts Set New Price Targets

Separately, Oppenheimer raised their price objective on Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a research report on Friday, September 6th.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.